Focal adhesion kinase promotes metastasis in BRAF-mutant melanoma
Preprint
Abstract
Despite the availability of several FDA-approved therapies, metastatic melanoma remains a significant clinical challenge, particularly for patients with brain metastases, which frequently represent the site of treatment failure and a major cause of melanoma-related mortality. Melanoma exhibits a strong propensity to metastasize to the brain, yet the molecular mechanisms driving this lethal progression remain incompletely understood, limiting the development of effective treatment options. Building on our prior discovery that focal adhesion kinase (FAK) is a key mediator of AKT1-driven brain metastasis, we sought to validate the role of FAK in melanoma progression and metastatic dissemination. Using complementary autochthonous and syngeneic mouse models of BRAF-mutant melanoma, we evaluated the impact of FAK expression on overall survival, primary tumor growth, and metastasis. Through the generation of targeted FAK mutants, we distinguished kinase-dependent from kinase-independent functions and demonstrate that FAK promotes melanoma metastasis in a kinase-dependent manner. Furthermore, we establish that FAK functions downstream of PTEN to drive metastatic progression. Collectively, these findings support the therapeutic potential of FAK inhibition, either alone or in combination with existing treatments, to more effectively combat metastatic melanoma and inform the development of emerging FAK-targeted therapies.Keywords
Funding Information
- National Cancer Institute (T32CA265782)
- National Cancer Institute (F31CA254307)
- National Cancer Institute (R01CA121118)
This publication has 45 references indexed in Scilit:
- FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanomaCancer Cell, 2025
- Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progressionClinical and Translational Oncology, 2024
- Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degradersBiochemical Pharmacology, 2024
- The biology and therapeutic management of melanoma brain metastasesBiochemical Pharmacology, 2018
- Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead miceThe Journal of Pathology, 2017
- AKT1 Activation Promotes Development of Melanoma MetastasesCell Reports, 2015
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor ImmunityCell, 2015
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK SignalingCancer Cell, 2015
- FAK dimerization controls its kinase‐dependent functions at focal adhesionsThe EMBO Journal, 2014
- Structural Basis for the Autoinhibition of Focal Adhesion KinaseCell, 2007